TORONTO–(BUSINESS WIRE)–Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company...
Toronto-based Cybin Inc. (NYSE:CYBN) will be raising roughly $150 million through the private placement of more than 348 million common shares to continue...
Toronto-based Cybin Inc. (NYSE:CYBN) will be raising roughly $150 million through the private placement of more than 348 million common shares to continue...
What does this mean for the psychedelic industry? In the ever-evolving landscape of biopharmaceutical investments, a notable shift is occurring, drawing...
NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) — Psyence Group Inc (“Psyence Group“) (CSE: PSYG), a clinical-stage life science biotechnology company...
NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) — Psyence Group Inc (“Psyence Group“) (CSE: PSYG), a clinical-stage life science biotechnology company...
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) chief scientific officer Dr Srinivas Rao discusses the company’s development candidate VLS-01, aimed at treating...
TORONTO, March 11, 2024 (GLOBE NEWSWIRE) — Further to the announcement by Psyence Group Inc (“Psyence Group” or the “Company“) (CSE:PSYG) of...
In a landmark study on the “moral status” of psilocybin, nearly 9 out of 10 Americans have voiced their approval for the controlled, licensed use of...
The new Nasdaq-listed entity trades under the ticker symbol PBM. The post Australia approves Psyence phase 2b study as it finalizes merger appeared first...